

IPW



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 27, 2007
Date Linda Murphy West

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David S. Burt et al.
Application No. : 10/771,737
Filed : February 3, 2004
For : PROTEOSOME INFLUENZA VACCINE
Art Unit : 1648
Examiner : Agnieszka Boesen, Ph.D.
Docket No. : 484112.410D1
Date : February 27, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the three (3) references set forth on the attached Information Disclosure Statement. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the U.S. Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of that is

03/06/2007 HVUONG1 00000010 10771737

01 FC:1806 180.00 OP

believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Director is authorized to charge any other fees that may be required or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Mae Joanne Rosok
Registration No. 48,903

MJR:lw

Enclosures:

Information Disclosure Statement
References Cited (3)

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

884574_1.DOC

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

484112.410D1

APPLICATION NO.

10/771,737

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

David S. Burt et al.

FILING DATE

February 3, 2004

GROUP ART UNIT

1648

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AD					
AE					
AF					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AG		Wetzler et al., "Gonococcal Porin Vaccine Evaluation: Comparison of Por Proteosomes, Liposomes, and Blebs Isolated from rmp Deletion Mutants," <i>Journal of Infectious Diseases</i> 166(3):551-555, September 1992.
AH		Wetzler et al., "Characterization and Specificity of Antibodies to Protein I of <i>Neisseria Gonorrhoeae</i> Produced by Injection with Various Protein I-Adjuvant Preparations," <i>Journal of Experimental Medicine</i> 168(5):1883-1897, November 1988.
AI		Zollinger et al., "Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man," <i>Journal of Clinical Investigation</i> 63(5):836-848, May 1979.
AJ		
AK		
AL		
AM		
AN		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).